The University of Nebraska Medical Center and Nebraska Medicine are participating in an international clinical trial to evaluate the safety and effectiveness of Novavax COVID-19 vaccine for adults.
Novavax vaccine is a protein-based vaccine from the coronavirus spike protein and is adjuvanted with saponin-based Matrix-M™ to enhance the immune response and stimulate high levels of neutralizing antibodies. It does not contain live virus, it cannot replicate, nor cause COVID-19.
Initially in the trial, two of three participants received vaccine and one of three received placebo. At this point, participants who first received the vaccine will receive placebo, and participants who received placebo first will now receive the vaccine. This crossover design ensures the administration of active vaccine to all participants in the trial. Crossover participants will remain blinded to their courses of treatment to preserve the ability to assess efficacy of the Novavax vaccine. All participants will be followed for up to two years to monitor the safety and durability of the protection from the vaccine.
The company is now expanding the vaccine trial to include adolescents. If you would like to be notified about the opportunity to participate in the adolescent trial, you can email us at firstname.lastname@example.org